Multiple Myeloma
June 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Multiple Myeloma abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Multiple Myeloma. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Multiple Myeloma. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Multiple Myeloma every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:How is patient care for multiple myeloma advancing?
Authors:Genadieva Stavric S, Bonello F, Bringhen S, Boccadoro M, Larocca A
Institution:a Medical Faculty , University Hematology Clinic , Skopje , Macedonia. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy.
Journal:Expert Rev Hematol. 2017 Jun;10(6):551-561. doi: 10.1080/17474086.2017.1326814. Epub 2017 May 19.

2:Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study.
Authors:Leng Y, Hou J, Jin J, Zhang M, Ke X, Jiang B, Pan L, Yang L, Zhou F, Wang J, Wang Z, Liu L, Li W, Shen Z, Qiu L, Chang N, Li J, Liu J, Pang H, Meng H, Wei P, Jiang H, Liu Y, Zheng X, Yang S, Chen W
Institution:Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. University, Shanghai, China. Zhejiang University, Hangzhou, Zhejiang, China. Shanxi, China. Hospital, Beijing, China. Sichuan, China. Taiyuan, Shanxi, China. China. Shanghai, China. University, Beijing, China. Xi'an, Shanxi, China. Jilin, China. Shanghai, China. Hospital, CAMS & PUMC, Tianjin, China. China. Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. Changsha, Hunan, China. Zhejiang University, Hangzhou, Zhejiang, China. University, Shanghai, China. Hospital, Beijing, China.
Journal:Cancer Chemother Pharmacol. 2017 Jun;79(6):1141-1149. doi: 10.1007/s00280-017-3310-0. Epub 2017 May 12.

3:The safety of daratumumab for the treatment of multiple myeloma.
Authors:Cejalvo MJ, Ribas P, de la Rubia J
Institution:a Hematology Service , University Hospital Doctor Peset , Valencia , Spain. "San Vicente Martir" , Valencia , Spain.
Journal:Expert Opin Drug Saf. 2017 Jun;16(6):753-760. doi: 10.1080/14740338.2017.1328053. Epub 2017 May 22.

4:Triplet versus doublet combination regimens for the treatment of relapsed or refractory multiple myeloma: A meta-analysis of phase III randomized controlled trials.
Authors:Sun Z, Zheng F, Wu S, Liu Y, Guo H, Liu Y
Institution:Department of Heamatology, Shenzhen Hospital of Southern Medical University, Shenzhen 518101, China. Electronic address: zhiqiangsun2016@sina.com. University, Guiyang 550014, China. China. China. China. China.
Journal:Crit Rev Oncol Hematol. 2017 May;113:249-255. doi: 10.1016/j.critrevonc.2017.03.018. Epub 2017 Mar 18.

5:Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses.
Authors:Aguiar PM, de Mendonca Lima T, Colleoni GWB, Storpirtis S
Institution:Department of Pharmacy, University of Sao Paulo, Sao Paulo, Brazil. Electronic address: aguiar.pm@usp.br. University of Sao Paulo, Sao Paulo, Brazil.
Journal:Crit Rev Oncol Hematol. 2017 May;113:195-212. doi: 10.1016/j.critrevonc.2017.03.014. Epub 2017 Mar 16.

6:Which therapies will move to the front line for multiple myeloma?
Authors:Cejalvo MJ, de la Rubia J
Institution:a Hematology Service , University Hospital Doctor Peset , Valencia , Spain. Martir" , Valencia , Spain.
Journal:Expert Rev Hematol. 2017 May;10(5):383-392. doi: 10.1080/17474086.2017.1317589. Epub 2017 Apr 24.

7:Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.
Authors:Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA
Institution:Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN. Electronic address: dingli.david@mayo.edu. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN. MN.
Journal:Mayo Clin Proc. 2017 Apr;92(4):578-598. doi: 10.1016/j.mayocp.2017.01.003. Epub 2017 Mar 11.

8:Immunotherapy for the treatment of multiple myeloma.
Authors:Jung SH, Lee HJ, Vo MC, Kim HJ, Lee JJ
Institution:Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, Republic of Korea; Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, Republic of Korea. Hospital, Hwasun, Jeollanamdo, Republic of Korea. Hospital, Hwasun, Jeollanamdo, Republic of Korea. Hwasun, Jeollanamdo, Republic of Korea. Hwasun, Jeollanamdo, Republic of Korea; Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, Republic of Korea. Electronic address: drjejung@chonnam.ac.kr.
Journal:Crit Rev Oncol Hematol. 2017 Mar;111:87-93. doi: 10.1016/j.critrevonc.2017.01.011. Epub 2017 Jan 27.

9:Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.
Authors:van Beurden-Tan CHY, Franken MG, Blommestein HM, Uyl-de Groot CA, Sonneveld P
Institution:Chrissy H.Y. van Beurden-Tan and Pieter Sonneveld, Erasmus MC Cancer Institute; Margreet G. Franken, Hedwig M. Blommestein, and Carin A. Uyl-de Groot, Erasmus University Rotterdam, Rotterdam; and Hedwig M. Blommestein and Carin A. Uyl-de Groot, Comprehensive Cancer Organisation, Utrecht, the Netherlands. Margreet G. Franken, Hedwig M. Blommestein, and Carin A. Uyl-de Groot, Erasmus University Rotterdam, Rotterdam; and Hedwig M. Blommestein and Carin A. Uyl-de Groot, Comprehensive Cancer Organisation, Utrecht, the Netherlands. Margreet G. Franken, Hedwig M. Blommestein, and Carin A. Uyl-de Groot, Erasmus University Rotterdam, Rotterdam; and Hedwig M. Blommestein and Carin A. Uyl-de Groot, Comprehensive Cancer Organisation, Utrecht, the Netherlands. Margreet G. Franken, Hedwig M. Blommestein, and Carin A. Uyl-de Groot, Erasmus University Rotterdam, Rotterdam; and Hedwig M. Blommestein and Carin A. Uyl-de Groot, Comprehensive Cancer Organisation, Utrecht, the Netherlands. Margreet G. Franken, Hedwig M. Blommestein, and Carin A. Uyl-de Groot, Erasmus University Rotterdam, Rotterdam; and Hedwig M. Blommestein and Carin A. Uyl-de Groot, Comprehensive Cancer Organisation, Utrecht, the Netherlands.
Journal:J Clin Oncol. 2017 Apr 20;35(12):1312-1319. doi: 10.1200/JCO.2016.71.1663. Epub 2017 Feb 27.

10:A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
Authors:Berenson J, Manges R, Badarinath S, Cartmell A, McIntyre K, Lyons R, Harb W, Mohamed H, Nourbakhsh A, Rifkin R
Institution:Institute for Myeloma and Bone Cancer Research, West Hollywood, California.
Journal:Am J Hematol. 2017 May;92(5):460-466. doi: 10.1002/ajh.24687. Epub 2017 Mar 22.

11:Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy.
Authors:Berdeja JG, Bauer T, Arrowsmith E, Essell J, Murphy P, Reeves JA Jr, Boccia RV, Donnellan W, Flinn I
Institution:Sarah Cannon Research Institute, Nashville, TN, USA.
Journal:Br J Haematol. 2017 Apr;177(2):254-262. doi: 10.1111/bjh.14536. Epub 2017 Feb 7.

12:Multiple myeloma: routes to diagnosis, clinical characteristics and survival - findings from a UK population-based study.
Authors:Howell D, Smith A, Appleton S, Bagguley T, Macleod U, Cook G, Patmore R, Roman E
Institution:Epidemiology & Cancer Statistics Group, Department of Health Sciences, University of York, York, UK. of York, York, UK. of York, York, UK. of York, York, UK. UK. of York, York, UK.
Journal:Br J Haematol. 2017 Apr;177(1):67-71. doi: 10.1111/bjh.14513. Epub 2017 Feb 1.

13:Safety issues and management of toxicities associated with new treatments for multiple myeloma.
Authors:Brioli A, Mugge LO, Hochhaus A, Von Lilienfeld-Toal M
Institution:a Klinik fur Innere Medizin II, Abt. Hamatologie und Internistische Onkologie , Universitatsklinikum Jena , Jena , Germany. Heinrich-Braun-Klinikum , Zwickau , Germany. Universitatsklinikum Jena , Jena , Germany. Universitatsklinikum Jena , Jena , Germany.
Journal:Expert Rev Hematol. 2017 Mar;10(3):193-205. doi: 10.1080/17474086.2017.1284584. Epub 2017 Jan 27.

14:Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Authors:Boudreault JS, Touzeau C, Moreau P
Institution:a Hematology Department , University Hospital Hotel-Dieu , Nantes , France.
Journal:Expert Rev Hematol. 2017 Mar;10(3):207-215. doi: 10.1080/17474086.2017.1285694. Epub 2017 Feb 9.

15:Emerging treatment approaches for myeloma-related bone disease.
Authors:Gavriatopoulou M, Dimopoulos MA, Kastritis E, Terpos E
Institution:a Department of Clinical Therapeutics , National and Kapodistrian University of Athens School of Medicine , Athens , Greece. Athens School of Medicine , Athens , Greece. Athens School of Medicine , Athens , Greece. Athens School of Medicine , Athens , Greece.
Journal:Expert Rev Hematol. 2017 Mar;10(3):217-228. doi: 10.1080/17474086.2017.1283213. Epub 2017 Jan 29.

16:Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Authors:Gavriatopoulou M, Terpos E, Kastritis E, Dimopoulos MA
Institution:a Department of Clinical Therapeutics , National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital , Athens , Greece. Athens, School of Medicine, Alexandra General Hospital , Athens , Greece. Athens, School of Medicine, Alexandra General Hospital , Athens , Greece. Athens, School of Medicine, Alexandra General Hospital , Athens , Greece.
Journal:Expert Opin Drug Saf. 2017 Feb;16(2):237-245. doi: 10.1080/14740338.2017.1279603. Epub 2017 Jan 11.

17:Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.
Authors:Cohen YC, Zuckerman T, Yeshurun M, Perez G, Magen H, Henig I, Levi I, Shargian L, Trestman S, Rouvio U, Naparstek E, Ganon-Elazar E, Avivi I, Ram R
Institution:Department of Hematology, Tel-Aviv Sourasky Medical Center, Institute of Hematology, Weizman St. 6, Tel Aviv, Israel. yaelcoh@tlvmc.gov.il. yaelcoh@tlvmc.gov.il. Campus, Haifa, Israel. Tikva, Israel. Tikva, Israel. Campus, Haifa, Israel. Tikva, Israel. Hematology, Weizman St. 6, Tel Aviv, Israel. Hematology, Weizman St. 6, Tel Aviv, Israel. Campus, Haifa, Israel. Hematology, Weizman St. 6, Tel Aviv, Israel.
Journal:Ann Hematol. 2017 Feb;96(2):271-278. doi: 10.1007/s00277-016-2882-9. Epub 2016 Dec 30.

18:Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.
Authors:Raje NS, Moreau P, Terpos E, Benboubker L, Grzasko N, Holstein SA, Oriol A, Huang SY, Beksac M, Kuliczkowski K, Tai DF, Wooldridge JE, Conti I, Kaiser CJ, Nguyen TS, Cronier DM, Palumbo A
Institution:Massachusetts General Hospital, Boston, MA, USA. Greece. France. Centre, Lublin, Poland. Josep Carreras (IJC), Hospital Germans Trias i Pujol, Badalona, Spain. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy.
Journal:Br J Haematol. 2017 Mar;176(5):783-795. doi: 10.1111/bjh.14483. Epub 2016 Dec 22.

19:Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.
Authors:Mey UJ, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna CJ, Schmid M, Schmidt-Hieber M, Doerfel S, Fischer N, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Driessen C
Institution:Medical Oncology and Haematology, Kantonsspital Graubunden, Chur, Switzerland. Switzerland. Germany. Switzerland. Switzerland. Switzerland. Switzerland.
Journal:Br J Haematol. 2017 Mar;176(5):770-782. doi: 10.1111/bjh.14481. Epub 2016 Dec 16.

20:Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Authors:Salvini M, Bonello F, Boccadoro M, Larocca A
Institution:a Myeloma Unit, Division of Hematology , University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy.
Journal:Expert Rev Anticancer Ther. 2017 Jan;17(1):75-87. Epub 2016 Dec 9.

21:Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.
Authors:Malard F, Harousseau JL, Mohty M
Institution:Department of Haematology, Saint Antoine Hospital, Paris, France; INSERM UMRs 938, Paris, France; Universite Pierre et Marie Curie, Paris, France. Electronic address: malardf@yahoo.fr.; Centre Catherine de Sienne, Nantes, France.
Journal:Cancer Treat Rev. 2017 Jan;52:41-47. doi: 10.1016/j.ctrv.2016.11.005. Epub 2016 Nov 15.

22:A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Authors:Sanchez L, Vesole DH, Richter JR, Biran N, Bilotti E, McBride L, Anand P, Ivanovski K, Siegel DS
Institution:Rutgers New Jersey Medical School, Newark, NJ, USA. Medical Center, Hackensack, NJ, USA. Medical Center, Hackensack, NJ, USA. Medical Center, Hackensack, NJ, USA. Medical Center, Hackensack, NJ, USA. Medical Center, Hackensack, NJ, USA. Medical Center, Hackensack, NJ, USA. Medical Center, Hackensack, NJ, USA. Medical Center, Hackensack, NJ, USA.
Journal:Br J Haematol. 2017 Feb;176(3):440-447. doi: 10.1111/bjh.14429. Epub 2016 Nov 18.

23:Safety of proteasome inhibitors for treatment of multiple myeloma.
Authors:Schlafer D, Shah KS, Panjic EH, Lonial S
Institution:a Department of Hematology and Medical Oncology , Winship Cancer Institute of Emory University , Atlanta , GA , USA. Emory University , Atlanta , GA , USA. Emory University , Atlanta , GA , USA. Emory University , Atlanta , GA , USA.
Journal:Expert Opin Drug Saf. 2017 Feb;16(2):167-183. doi: 10.1080/14740338.2017.1259310. Epub 2016 Nov 28.

24:Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
Authors:Laubach JP, Paba Prada CE, Richardson PG, Longo DL
Institution:Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Journal:Clin Pharmacol Ther. 2017 Jan;101(1):81-88. doi: 10.1002/cpt.550.

25:Panobinostat for the management of multiple myeloma.
Authors:Sivaraj D, Green MM, Gasparetto C
Institution:Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA. Medical Center, Durham, NC, USA. Medical Center, Durham, NC, USA.
Journal:Future Oncol. 2017 Mar;13(6):477-488. doi: 10.2217/fon-2016-0329. Epub 2016 Oct 25.

26:Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma.
Authors:Wang C, He Z, Shi Y, Zhang L, Chen Y, Chen Z, Yu L
Institution:a Department of Hematology, Huai'an First People's Hospital , Nanjing Medical University , Huai'an 223300 , Jiangsu , China. University , Huai'an 223300 , Jiangsu , China. University , Huai'an 223300 , Jiangsu , China. University , Huai'an 223300 , Jiangsu , China. University , Huai'an 223300 , Jiangsu , China. University , Huai'an 223300 , Jiangsu , China. University , Huai'an 223300 , Jiangsu , China.
Journal:Hematology. 2017 Mar;22(2):88-92. doi: 10.1080/10245332.2016.1234186. Epub 2016 Sep 25.

27:The next generation of novel therapies for the management of relapsed multiple myeloma.
Authors:Gonsalves WI, Milani P, Derudas D, Buadi FK
Institution:The Divisions of Hematology & Blood & Marrow Transplantation, Mayo Clinic, Rochester, MN, USA. Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo & University of Pavia, Pavia, Italy. Rochester, MN, USA.
Journal:Future Oncol. 2017 Jan;13(1):63-75. Epub 2016 Aug 11.

28:Evaluation of low-dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation.
Authors:Aznab M, Rezaei M, Navabi J, Moieni A
Institution:Internal Medicine Department, Talaghani Hospital, Kermanshah University of Medical Science, Kermanshah, Iran. Center, Public Health College, Kermanshah University of Medical Sciences, Kermanshah, Iran. Medical Science, Kermanshah, Iran. Medical Science, Kermanshah, Iran.
Journal:Asia Pac J Clin Oncol. 2017 Apr;13(2):e138-e143. doi: 10.1111/ajco.12418. Epub 2015 Nov 4.

For a FREE PREVIEW of the Medifocus Guidebook on Multiple Myeloma click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Multiple Myeloma click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Multiple Myeloma...
at a Special 20% Discount


Medifocus Guidebook on Multiple Myeloma

Updated: June 21, 2017
188 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Multiple Myeloma is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MM42540918

Coupon Expires: August 25, 2017



What Our Customers Are Saying...

"The information in your MediFocus Guidebook on Multiple Myeloma was extremely useful. Thank you for providing this service."
K.J.
Milwaukee, Wisconsin


"I purchased the MediFocus Guidebook on Multiple Myeloma for my mother and it was a great help because it helped us to understand more about the disease, the causes, and the treatment options. Although there is no cure, it has helped us cope with the situation and helped us figure out how we can live with the disease."
J.M.
New York, New York


"My oncologist borrowed my copy of the MediFocus Guidebook on Multiple Myeloma and found it very useful in his work. He intends to contact your office."
D.S.
Miami Beach, Florida



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.